Metlife Inc MET
We take great care to ensure that the data presented and summarized in this overview for METLIFE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MET
View all-
Vanguard Group Inc Valley Forge, PA58MShares$5 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA54.2MShares$4.67 Billion2.77% of portfolio
-
Black Rock Inc. New York, NY47.5MShares$4.09 Billion0.08% of portfolio
-
State Street Corp Boston, MA26.7MShares$2.31 Billion0.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD24.7MShares$2.13 Billion0.23% of portfolio
-
Wellington Management Group LLP Boston, MA15MShares$1.29 Billion0.23% of portfolio
-
Jpmorgan Chase & CO New York, NY13.1MShares$1.13 Billion0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA11.9MShares$1.03 Billion0.08% of portfolio
-
Morgan Stanley New York, NY11.7MShares$1.01 Billion0.07% of portfolio
-
Norges Bank Oslo, Q88.92MShares$769 Million0.1% of portfolio
Latest Institutional Activity in MET
Top Purchases
Top Sells
About MET
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
Insider Transactions at MET
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 25
2025
|
Ramy Tadros President, U.S. Business |
SELL
Payment of exercise price or tax liability
|
Direct |
23,045
-11.01%
|
$1,889,690
$82.2 P/Share
|
Feb 25
2025
|
Ramy Tadros President, U.S. Business |
BUY
Grant, award, or other acquisition
|
Direct |
62,295
+13.61%
|
-
|
Feb 25
2025
|
John D. Mc Callion EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,704
-9.64%
|
$2,189,728
$82.2 P/Share
|
Feb 25
2025
|
John D. Mc Callion EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,284
+12.03%
|
-
|
Feb 25
2025
|
Michel Khalaf President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
82,227
-11.56%
|
$6,742,614
$82.2 P/Share
|
Feb 25
2025
|
Michel Khalaf President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
210,751
+13.55%
|
-
|
Feb 25
2025
|
Shurawl Sibblies EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,825
+7.7%
|
-
|
Feb 25
2025
|
Bill Pappas EVP, Global Tech. & Ops. |
SELL
Payment of exercise price or tax liability
|
Direct |
22,810
-20.18%
|
$1,870,420
$82.2 P/Share
|
Feb 25
2025
|
Bill Pappas EVP, Global Tech. & Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
62,005
+24.28%
|
-
|
Feb 25
2025
|
Marlene Debel EVP & Chief Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,706
-8.49%
|
$1,041,892
$82.2 P/Share
|
Feb 25
2025
|
Marlene Debel EVP & Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,200
+12.74%
|
-
|
Feb 25
2025
|
Tamara Schock EVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
169
-0.68%
|
$13,858
$82.2 P/Share
|
Feb 25
2025
|
Tamara Schock EVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,889
+16.34%
|
-
|
Feb 25
2025
|
Monica M Curtis EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,920
+16.13%
|
-
|
Jan 02
2025
|
William E Kennard Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+1.26%
|
$43,335
$81.78 P/Share
|
Jan 02
2025
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+2.52%
|
$43,335
$81.78 P/Share
|
Jan 02
2025
|
Carla A Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+6.8%
|
$43,335
$81.78 P/Share
|
Jan 02
2025
|
Jeh C. Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+8.71%
|
$43,335
$81.78 P/Share
|
Jan 02
2025
|
Robert Glenn Hubbard Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+0.93%
|
$74,358
$81.78 P/Share
|
Jan 02
2025
|
Denise M Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+1.66%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 517K shares |
---|---|
Exercise of conversion of derivative security | 48.9K shares |
Payment of exercise price or tax liability | 168K shares |
---|---|
Open market or private sale | 74.8K shares |